Report How to evaluate transparent PBMs with confidence: A guide for benefits advisors
Clean pricing, broken results. Stop trusting the RFP and start evaluating what actually delivers for your clients.
Pharmacy benefit management
Benefits Think PBM playbook, part 2: Changes to the market and the value of a pharmacy benefits expert
A look at traditional PBMs and pass-through models, potential savings areas, developments and partnering with the right consultant.
Report An industry in flux: How to navigate the complex pharmacy benefits landscape with confidence
If you advise self-funded employers, this report equips you to guide clients in the fast-changing 2026 PBM landscape.
Congress’ push to rein in drug costs will impact benefit strategies
New drug pricing proposals could reshape employer pharmacy strategy, as benefit managers struggle to navigate rising prescription costs.
Cigna will end drug rebates in many private health plans
The plan to eventually phase out rebates portends a seismic shift in the flow of billions of dollars among drugmakers, insurers and employers.
White paper Transparency and innovative cost-containment strategies are the keys to reducing pharmaceutical costs
HR and benefits leaders have a significant opportunity to expand their playbooks with proven methods to overcome their most intractable challenge.
Preparing for open enrollment: Rx benefits redesign holds promise for cost control
Key to cost containment lies in partnering with transparent PBMs, a more thoughtful approach to prescribing GLP-1s and encouraging the uptake of biosimilars.
Coalition PBMs: Bigger isn’t always better
Without the right contractual terms in place, hidden costs may mar pooled purchasing power at the expense of employer clients.
Why this benefit leader switched to a more modern, transparent PBM
Rice University's executive director of HR operations ditched a traditional model for one that's providing lower costs and better customer service.
Vigilance on vetting PBMs will stem litigation
Amid high-profile, class-action lawsuits over inflated prescription drug prices, advisers are urged to cement a fiduciary process for employer clients.
Benefits Think A 5-point checklist for CAA compliance on Rx fiduciary oversight
Definitive steps can be taken to strategically optimize pharmacy benefits in a way that balances cost with quality care.
Greg Sanderson
AlignRx
Benefits Think 3 PBM programs and capabilities to consider beyond unit cost
Examine adaptability and foresight to understand the intricacies of an evolving pharmaceutical market.
Greg Sanderson
AlignRx
Benefits Think The quest to enhance PBM transparency and accountability
Bipartisan support is building to make pharmacy benefit managers more transparent and accountable, which would benefit millions of working Americans.
Melissa Bartlett
The ERISA Industry Committee
Cigna offers prescription price transparency after facing scrutiny
The insurance giant's pharmacy-benefit management unit will market a "fully transparent" option charging a flat monthly fee for each member.
Why this pharmacy benefit manager is using a value-based model to tackle rising drug costs
Karthik Ganesh, CEO of EmpiRx Health, explains why his company stands by a value-based model when working with employers.
Benefits Think How to secure good PBM contract terms
It starts with rejecting subjective concepts and demanding objective pricing metrics.
Terrance Killilea
USI Insurance Services
Ask an Adviser: How can pharmacists improve care by picking up where PBM services leave off?
A team-based care model is extremely effective at improving clinical outcomes for high-risk patients with chronic conditions and lowering healthcare costs.
How this company is guaranteeing the lowest drug prices
Here’s how healthcare company, Capital Rx, is bringing pharmacy benefit management solutions to consumers in the wake of rapidly increasing drug costs.
An attorney shares the warning signs of ‘self-serving’ PBMs
Dae Lee, pharmacist attorney for healthcare and life sciences law firm, Frier Levitt, reflects on the role PBMs have played in the healthcare industry.
Is the pharmaceutical industry due for change?
Should employers increasingly consider cutting out the middle man in the prescription drug procurement pipeline?
